Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
Supervisors: Dr Tim Halim and Dr Gregory Hamm Course start: 1st October 2026 Overview The project will be supervised by Dr Tim Halim, Dr Albert Koulman (Institute of Metabolic Science) and Dr Gregory Hamm (AstraZeneca). Project details The tumour immunity cycle involves cyclical trafficking of...
-
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner) Course start date: 1st October 2026 Project details Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy
-
Targeting Cardiometabolic Dysfunction in Heart Failure with Preserved Ejection Fraction (HFpEF): Mechanisms of Exercise-Induced Protection Overview Applications are invited for a fully funded 4-year
-
target, since all known treatment resistance mechanisms are downstream of, and dependent on FOXA1. However, FOXA1 has been a difficult protein to study for technical reasons. We have developed a novel tool
-
treatments that target AR have forced cancer cells to evade treatment and a newly characterised, but frequent escape mechanism is for cancer cells to lose dependence on AR and to take on features of a
-
required to meet their climate neutrality targets (see: https://up2030-he.eu/ ). The University of Cambridge is leading activities on data governance and city-wide carbon management. The post holder will be
-
track record in the fields of immunology or infectious diseases, compelling research plans that complement ongoing work at CITIID, and a strong commitment to contributing to a positive, collaborative
-
) in a relevant subject (Physics, Chemistry, Materials Science, Chemical Engineering), experimental track record and willingness to learn. Home rate fees are fully funded. Applicants from overseas will